High-sensitivity C-reaction protein crucial for predicting CV risk after PCI, study reveals
China: A recent study has shown elevated high-sensitivity C-reaction protein (hsCRP) to be an independent risk factor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention (PCI), with or without diabetes mellitus. The findings from the landmark prospective cohort study were published in BMC Cardiovascular Diabetology.
The study by Le Li and colleagues has illuminated a new dimension in predicting cardiovascular outcomes after PCI - a common procedure for treating coronary artery stenosis. The study, conducted on a massive scale with 8,050 participants, has underscored the significance of hsCRP, a biomarker associated with residual inflammatory risk.
The findings gathered over a median follow-up of 35.7 months, have far-reaching implications for both diabetic and non-diabetic patients, heralding a novel era of personalized risk assessment in cardiovascular care.
In a bid to evaluate the prognostic value of hsCRP, the study segregated patients into four categories based on their hsCRP levels and diabetic status: hsCRP-L/non-DM, hsCRP-H/non-DM, hsCRP-L/DM, and hsCRP-H/DM. The primary endpoint, termed major adverse cardiovascular events (MACEs), encompassed a spectrum of outcomes including all-cause mortality, myocardial infarction, stroke, and unplanned vessel revascularization. Over a three-year follow-up period, the study scrutinised these outcomes against hsCRP levels.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.